MGNX News and Press, MacroGenics Inc. From 03/08/24

2024-03-08 00:30:17 ET Image source: The Motley Fool. MacroGenics (NASDAQ: MGNX) Q4 2023 Earnings Call Mar 07, 2024 , 4:30 p.m. ET Operator Continue reading For further details see: MacroGenics (MGNX) Q4 2023 Earnings Call Transcript

2024-03-07 23:30:29 ET MacroGenics, Inc. (MGNX) Q4 2023 Earnings Conference Call March 07, 2024, 04:30 PM ET Company Participants Jim Karrels - Senior Vice President and Chief Financial Officer Scott Koenig - President and Chief Executive Officer Conference Cal...

2024-03-07 16:12:26 ET More on MacroGenics MacroGenics: Evaluating Its Buy Status After A 200% Surge On Prostate Cancer Prospects MacroGenics: Trying To Build A Better Everything MacroGenics Q4 2023 Earnings Preview MacroGenics stock climbs 13% in wake of upg...

Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024 Initiation of Phase 1 study of MGC026, MacroGenics' first topoisomerase I inhibitor-based ADC Preclinical data on two topoisomerase I inhibitor-based ADC product candi...

Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...

2024-03-06 17:35:33 ET Major earnings expected after the bell on Thursday include: Costco Wholesale Corporation ( COST ) Broadcom ( AVGO ) DocuSign ( DOCU ) Marvell Technology ( MRVL ) Petróleo Brasileiro ( PBR ) Read the full article o...

2024-03-05 16:42:18 ET Gainers: Ebang International Holdings  ( EBON ) +17% . CrowdStrike Holdings ( CRWD ) +17% . Couchbase ( BASE ) +14% . SOPHiA GENETICS ( SOPH ) +6% . Expensify ( EXFY ) +5% . Losers: ODDITY Tech...

MacroGenics, Inc. (NASDAQ: MGNX) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.3% on the day to $20.99. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved p...

ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its finan...

2024-02-19 22:23:22 ET Summary MacroGenics' stock has increased by 230% since September due to favorable macroeconomics and interest in antibody-drug conjugates. The company is testing vobramitamab duocarmazine for the treatment of metastatic castration-resistant prostate cancer. ...